"These findings are consistent with the Phase 3 data showing the effectiveness of extended-release buprenorphine in addressing opioid dependence, including among patients using fentanyl", says
Of 428 trial participants, 123 (SC-BPN, n=64; SL-BPN/NX, n=59) had evidence of baseline fentanyl use. In the fentanyl-positive subgroup, the mean percentage of urine samples negative for fentanyl during the study was 74% for the SC-BPN arm versus 61.9% for the SL BPN/NX arm). Withdrawal symptoms and cravings decreased following treatment initiation in patients positive for fentanyl use at baseline. No substantial difference was observed in rates of study completion between fentanyl-positive and fentanyl-negative cohorts (60.2% and 56.7%, respectively). The safety profile of SC-BPN was comparable to the known safety profile of buprenorphine, with the exception of mild to moderate injection site reactions
"The publication features a unique data set collected during the wake of the fentanyl crisis in the US and suggests that buprenorphine, in particular weekly and monthly subcutaneous injections, is effective in treating opioid dependence including in patients who use fentanyl", says
The full publication "Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder with Fentanyl Use" is available online at JAMA Network Open today.2
For more information
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Buvidal®
Buvidal (buprenorphine prolonged-release solution for subcutaneous injection in prefilled syringe) is indicated for the treatment of opioid dependence within a framework of medical, social, and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.3Buvidal is available in four weekly strengths (8mg, 16mg, 24mg and 32mg) and four monthly strengths (64mg, 96mg, 128mg and 160mg), enabling treatment to be tailored to the patient's individual needs.
Buvidal is approved for treatment of opioid dependence in the EU,
About
References
- Lofwall, MR, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(6):764-773. doi:10.1001/jamainternmed.2018.1052.
- Nunes, E. V., et al. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder with Fentanyl Use. JAMA Network Open. 2024;7(6):e2417377.doi10.1001/jamanetworkopen.2024.17377.
- SmPC Buvidal,
Aug 2023
This information was submitted for publication at
https://news.cision.com/camurus-ab/r/new-publication-shows-effectiveness-data-for-weekly-and-monthly-buprenorphine-injections-in-treating,c4006361
https://mb.cision.com/Main/13456/4006361/2884599.pdf
(c) 2024 Cision. All rights reserved., source